.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Baxter
Accenture
McKinsey
Citi
Johnson and Johnson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Naproxen sodium; sumatriptan succinate - Generic Drug Details

« Back to Dashboard

What are the generic sources for naproxen sodium; sumatriptan succinate and what is the scope of naproxen sodium; sumatriptan succinate freedom to operate?

Naproxen sodium; sumatriptan succinate
is the generic ingredient in one branded drug marketed by Pernix Ireland Ltd and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naproxen sodium; sumatriptan succinate has thirty-three patent family members in sixteen countries and ten supplementary protection certificates in eight countries.

There are forty-two drug master file entries for naproxen sodium; sumatriptan succinate. Three suppliers are listed for this compound.

Summary for naproxen sodium; sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-001Apr 15, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-001Apr 15, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-001Apr 15, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-001Apr 15, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: naproxen sodium; sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pernix Ireland LtdTREXIMETnaproxen sodium; sumatriptan succinateTABLET;ORAL021926-001Apr 15, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: naproxen sodium; sumatriptan succinate

Country Document Number Estimated Expiration
Cyprus1112640► Subscribe
Spain2234025► Subscribe
Denmark1575566► Subscribe
Japan4616009► Subscribe
European Patent Office0957914► Subscribe
Australia2003303631► Subscribe
Japan2000506541► Subscribe
Australia3984597► Subscribe
Australia711741► Subscribe
Hong Kong1023517► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90013-1Sweden► SubscribePRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
11/016Ireland► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
C/GB11/013United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
2011005,C0984957Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900/01Switzerland► SubscribePRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
2012 00035Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
00481Netherlands► SubscribePRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
2012000051Germany► SubscribePRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
2011005Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Queensland Health
Mallinckrodt
Baxter
Accenture
Citi
Express Scripts
Fish and Richardson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot